Research programme: recombinant antibodies - AnaptysBio/Momenta PharmaceuticalsAlternative Names: Anti-FcRn antibody - Momenta Pharmaceuticals
Latest Information Update: 01 Dec 2014
At a glance
- Originator AnaptysBio
- Developer Momenta Pharmaceuticals
- Class Antibodies; Monoclonal antibodies
- Mechanism of Action Fc receptor antagonists; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders